Verzenios® ▼ (abemaciclib): Dosering och administreringssätt

Recommended Dosing

The recommended dose of abemaciclib is 150 mg twice daily when used in combination with endocrine therapy. ¹

Please refer to the Summary of Product Characteristics of the endocrine therapy combination partner for the recommended posology. ¹

Abemaciclib  should be taken continuously as long as the patient is deriving clinical benefit from therapy or until unacceptable toxicity occurs.¹

Administration

Abemaciclib  is for oral use.¹

The dose can be taken with or without food. It should not be taken with grapefruit or grapefruit juice.¹

Patients should take the doses at approximately the same times every day.

The tablet should be swallowed whole (patients should not chew, crush, or split tablets before swallowing).¹

Abemaciclib tablets are not scored and are not designed to be split or divided into smaller doses. Abemaciclib is approved for oral administration only. It is not available as a parenteral product for IV administration.²

Dose Modification

Management of some adverse reactions may require dose interruption and/or dose reduction.¹

CYP3A Inducers and Inhibitors

Abemaciclib is primarily metabolised by CYP3A4.¹

Concomitant use of CYP3A4 inducers should be avoided due to the risk of decreased efficacy of abemaciclib.¹

Use of strong CYP3A4 inhibitors together with abemaciclib should be avoided. If strong CYP3A4 inhibitors need to be co-administered, the dose of abemaciclib should be reduced, followed by careful monitoring of toxicity.¹

If the CYP3A4 inhibitor is discontinued, the abemaciclib dose should be increased to the dose used prior to the initiation of the CYP3A4 inhibitor (after 3 to 5 half-lives of the CYP3A4 inhibitor).¹

Please see Summary of Product Characteristics for instructions for dose modification, which may be needed for patients taking CYP3A4 inhibitors. ¹

Hepatic Impairment

No dose adjustments are necessary in patients with mild (Child Pugh A) or moderate (Child Pugh B) hepatic impairment.¹ 

In patients with severe (Child Pugh C) hepatic impairment, a decrease in dosing frequency to once daily is recommended.¹

Overdose

In the event of an abemaciclib overdose, fatigue and diarrhoea may occur. General supportive care should be provided.¹

There is no known antidote for abemaciclib overdose.²

References

1. Verzenios [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Glossary

CYP = cytochrome P450

IV = intravenous

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.